Abstract
We investigated serum ghrelin levels (SGL) in 12 patients with schizophrenia over a 10-week period after initiation of clozapine treatment. In contrast to increments of body mass indices (BMI, kg/m2) and serum leptin levels (SLL), no significant change in SGL was detected. Inverse correlations between delta SGL and delta SLL did not reach statistical significance. Linear mixed model analysis could not detect effects of age, sex, BMI, SLL and serum clozapine levels on SGL. Our results do not support a causal involvement of ghrelin in clozapine-related weight gain.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antipsychotic Agents / administration & dosage
-
Antipsychotic Agents / adverse effects*
-
Body Mass Index
-
Clozapine / administration & dosage
-
Clozapine / adverse effects*
-
Female
-
Ghrelin
-
Humans
-
Leptin / blood
-
Longitudinal Studies
-
Male
-
Peptide Hormones / blood*
-
Prospective Studies
-
Schizophrenia / blood*
-
Schizophrenia / drug therapy*
-
Schizophrenia, Catatonic / blood
-
Schizophrenia, Catatonic / drug therapy
-
Schizophrenia, Disorganized / blood
-
Schizophrenia, Disorganized / drug therapy
-
Schizophrenia, Paranoid / blood
-
Schizophrenia, Paranoid / drug therapy
-
Weight Gain / drug effects
Substances
-
Antipsychotic Agents
-
Ghrelin
-
Leptin
-
Peptide Hormones
-
Clozapine